Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-mesothelin ODC
- Development stage
- Preclinical
- Lead developer
- Affilogic
- Modality
- Peptide-Drug Conjugates → Peptide Conjugates → Peptides
- Administration
- Intravenous
01
Overview
Anti-mesothelin ODC (OncoFitin-Drug-Conjugate) is a preclinical-stage nanofitin-drug conjugate (NDC) being developed by Affilogic for the treatment of mesothelin-expressing solid tumors, including mesothelioma, ovarian cancer, and pancreatic cancer. The therapeutic consists of a Nanofitin—a small (7 kDa), robust affinity protein derived from the extremophilic archaeon *Sulfolobus acidocaldarius*—engineered to bind specifically to mesothelin. This targeting moiety is conjugated to the cytotoxic payload monomethyl auristatin E (MMAE). Upon binding to mesothelin on the tumor cell surface, the conjugate is internalized, releasing MMAE to disrupt microtubule dynamics, leading to cell cycle arrest and apoptosis. The Nanofitin platform is designed to offer advantages over traditional antibody-drug conjugates (ADCs), such as smaller size for better tissue penetration and high stability.
- Other names
- OncoFitin-Drug-Conjugateanti-Mesothelin Nanofitin-drug conjugateanti-Mesothelin ODC
02
Targets
TUBB (Tubulin (alpha and beta subunits))Mesothelin
Beyond the preview
Go deeper on anti-mesothelin ODC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-mesothelin ODC.